TAKHZYRO™
(lanadelumab-flyo) injection

NOW APPROVED

TAKHZYRO IS A FIRST-OF-ITS-KIND MAB PREVENTIVE TREATMENT FOR HEREDITARY ANGIOEDEMA (HAE)[1]

JOIN US TO LEARN MORE ABOUT:

- The pathophysiology of hereditary angioedema (HAE) and the impact it has on patients
- TAKHZYRO (lanadelumab-flyo): A first-of-its-kind mAb injectable medicine for prophylaxis to prevent attacks of HAE in patients 12 years and older
  - The recommended starting dose is 300 mg every 2 weeks. A dosing interval of 300 mg every 4 weeks is also effective and may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months.

TO REGISTER, PLEASE CALL
877-761-7925 OR VISIT
www.programrsvp.com/2695-39

TAKHZYRO is available as a 300 mg dose

PRESENTER:
William R. Lumry, MD
Founder
Allergy & Asthma Specialists of Dallas
Dallas, TX

WHEN:
Friday, April 26, 2019
7:00 PM ET

WHERE:
Washington Duke Inn & Golf Club
3001 Cameron Boulevard
Durham, NC 27705

This program is open to healthcare professionals only. ***Please be advised that spouses and other guests are not permitted to participate.*** *Thank you in advance, and we look forward to your participation.*

This is not a CME program.

INDICATION

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Please see next page for additional Important Safety Information.

TAKHZYRO™
(lanadelumab-flyo) injection

IMPORTANT SAFETY INFORMATION (cont'd)

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp. (a wholly-owned, indirect subsidiary of Shire plc) at 1-800-828-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including information for patients.

Reference: 1. TAKHZYRO (lanadelumab-flyo) injection [prescribing information]. Lexington, MA: Shire Pharmaceuticals, Inc; 2018.

TAKHZYRO™
(lanadelumab-flyo) injection

Program sponsored by

Shire

S43349 10/18